These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 15380528)

  • 1. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
    Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
    Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efalizumab in the treatment of psoriasis.
    Boehncke WH
    Biologics; 2007 Sep; 1(3):301-9. PubMed ID: 19707339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple environmental antigens may trigger autoimmunity in psoriasis through T-cell receptor polyspecificity.
    Ishimoto T; Arakawa Y; Vural S; Stöhr J; Vollmer S; Galinski A; Siewert K; Rühl G; Poluektov Y; Delcommenne M; Horvath O; He M; Summer B; Pohl R; Alharbi R; Dornmair K; Arakawa A; Prinz JC
    Front Immunol; 2024; 15():1374581. PubMed ID: 38524140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human CLA
    de Jesús-Gil C; Sans-de San Nicolàs L; García-Jiménez I; Ferran M; Pujol RM; Santamaria-Babí LF
    Front Med (Lausanne); 2021; 8():731911. PubMed ID: 34778294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation.
    Gao Y; Lu J; Bao X; Yi X; Peng C; Chen W; Zhen T; Shi Y; Xing K; Zhu S; Ding Y
    Exp Biol Med (Maywood); 2021 Jun; 246(11):1253-1262. PubMed ID: 33641447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality.
    Mancuso RV; Casper J; Schmidt AG; Krähenbühl S; Weitz-Schmidt G
    Br J Pharmacol; 2020 Jun; 177(12):2696-2711. PubMed ID: 31985813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Analysis of Trafficking Receptors Shows that CD44 and P-Selectin Glycoprotein Ligand-1 Collectively Control the Migration of Activated Human T-Cells.
    Ali AJ; Abuelela AF; Merzaban JS
    Front Immunol; 2017; 8():492. PubMed ID: 28515724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pur-Alpha Induces JCV Gene Expression and Viral Replication by Suppressing SRSF1 in Glial Cells.
    Sariyer IK; Sariyer R; Otte J; Gordon J
    PLoS One; 2016; 11(6):e0156819. PubMed ID: 27257867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-Gamma Inhibits JC Virus Replication in Glial Cells by Suppressing T-Antigen Expression.
    De-Simone FI; Sariyer R; Otalora YL; Yarandi S; Craigie M; Gordon J; Sariyer IK
    PLoS One; 2015; 10(6):e0129694. PubMed ID: 26061652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
    Chahin S; Berger JR
    J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.
    Zaheer F; Berger JR
    Ther Adv Drug Saf; 2012 Oct; 3(5):227-39. PubMed ID: 25083238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune surveillance and response to JC virus infection and PML.
    Beltrami S; Gordon J
    J Neurovirol; 2014 Apr; 20(2):137-49. PubMed ID: 24297501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients.
    Li XP; Li J; Yan H; Zhou B; Li BH; Qian WZ; Hou S; Wang H; Hao F; Guo YJ
    Acta Pharmacol Sin; 2012 Aug; 33(8):1085-94. PubMed ID: 22796761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
    Johnson-Huang LM; Pensabene CA; Shah KR; Pierson KC; Kikuchi T; Lentini T; Gilleaudeau P; Sullivan-Whalen M; Cueto I; Khatcherian A; Hyder LA; Suárez-Fariñas M; Krueger JG; Lowes MA
    PLoS One; 2012; 7(2):e30308. PubMed ID: 22348003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.
    Schwab N; Ulzheimer JC; Fox RJ; Schneider-Hohendorf T; Kieseier BC; Monoranu CM; Staugaitis SM; Welch W; Jilek S; Du Pasquier RA; Brück W; Toyka KV; Ransohoff RM; Wiendl H
    Neurology; 2012 Feb; 78(7):458-67; discussion 465. PubMed ID: 22302546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.
    Manikwar P; Kiptoo P; Badawi AH; Büyüktimkin B; Siahaan TJ
    Med Res Rev; 2012 Jul; 32(4):727-64. PubMed ID: 21433035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LFA-1-specific therapy prolongs allograft survival in rhesus macaques.
    Badell IR; Russell MC; Thompson PW; Turner AP; Weaver TA; Robertson JM; Avila JG; Cano JA; Johnson BE; Song M; Leopardi FV; Swygert S; Strobert EA; Ford ML; Kirk AD; Larsen CP
    J Clin Invest; 2010 Dec; 120(12):4520-31. PubMed ID: 21099108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy and newer biological agents.
    Berger JR
    Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic inflammatory myopathies: current and future therapeutic options.
    Wiendl H
    Neurotherapeutics; 2008 Oct; 5(4):548-57. PubMed ID: 19019306
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.